HUMAN ANTITUMOR THERAPY WITH MONOCLONAL ANTIBODIES

使用单克隆抗体的人类抗肿瘤疗法

• 批准号: 3171295
• 金额: $ 41.16万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1982
• 资助国家: 美国
• 起止时间: 1982-07-01 至 1988-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3171295
• 关键词: B lymphocyte; T lymphocyte; adult human (21+); antiantibody; antibody specificity; antiidiotype antibody; antileukemic agent; antineoplastics; antitumor antibody; child (0-11); combination cancer therapy; cyclophosphamide; flow cytometry; human subject; human therapy evaluation; immunofluorescence technique; lymphocytic leukemia; lymphoma; monoclonal antibody; mycosis fungoides lymphoma; neoplasm /cancer immunotherapy; pediatric neoplasm /cancer; radioimmunoassay; serology /serodiagnosis

In this project we will continue clinical trials of monoclonal antibodies in human lymphoma. We will focus on B cell lymphoma using custom-made anti-idiotype antibodies since this is the area in which the best results have so far been obtained. Refinements will be made in patient selection, antibody development and production and mode of antibody administration in order to take advantage of the information generated in our earlier trials and to improve the clinical results. The clinical and biological correlates of tumor response will be defined by studies on the antibodies, the tumor and the host. Each patient's tumor will be studied for genetic heterogeneity by immunoglobulin gene rearrangements and by multiple different anti-idiotype antibodies. In this way, we hope to continue to gain insights into the biology of human lymphoid malignancy.

在这个项目中，我们将继续进行单克隆抗体的临床试验 在人类淋巴瘤中。 我们将使用定制制作的B细胞淋巴瘤专注于B细胞淋巴瘤 抗IDiotype抗体，因为这是最佳结果的区域 到目前为止已经获得了。 将在患者选择中进行改进， 抗体开发和生产和抗体给药模式 为了利用我们较早的试验中产生的信息 并改善临床结果。 临床和生物学 肿瘤反应的相关性将通过对抗体的研究来定义 肿瘤和宿主。 每个患者的肿瘤将被研究以进行遗传 免疫球蛋白基因重排的异质性和多个 不同的抗IDioty型抗体。 这样，我们希望继续 洞悉人类淋巴恶性肿瘤的生物学。